Duvyzat is a small molecule that works as a HDAC Inhibitor.[2] It is being investigated across 5 indications, with its most advanced program in Phase 3.[1]
Duvyzat is one of 74 small molecule programs targeting Tics. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
114 competitors in Tics
Duvyzat
Sodium Valproate
Priftin
Nydrazid
Dilaudid
CAB LA
Invokana
Tylenol
Rifampicin
Abexinostat
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Mar 21, 2024
DUVYZAT
NDA NDA217865
Mar 21, 2024
DUVYZAT
NDA NDA217865
Sources